Motilitone(®) (DA-9701) is a new herbal
drug that was launched for the treatment of functional
dyspepsia in December 2011 in Korea. The heterogeneous symptom pattern and multiple causes of functional
dyspepsia have resulted in multiple
drug target strategies for its treatment.
DA-9701, a compound consisting of a combination of Corydalis Tuber and Pharbitidis Semen, has being developed for treatment of functional
dyspepsia. It has multiple mechanisms of action such as fundus relaxation, visceral
analgesia, and prokinetic effects. Furthermore, it was found to significantly enhance meal-induced gastric accommodation and increase gastric compliance in dogs.
DA-9701 also showed an
analgesic effect in rats with colorectal distension induced visceral
hypersensitivity and an antinociceptive effect in beagle dogs with gastric distension-induced nociception. The pharmacological effects of
DA-9701 also include conventional effects, such as enhanced gastric emptying and gastrointestinal transit. The safety profi le of
DA-9701 is also preferable to that of other treatments.